Print Friendly, PDF & Email

NCT/Study#

NCT03420183 /

ONCTERNAL-CIRM-0001

A Phase 1b-2 Study Of The ROR1-Targeting Monoclonal Antibody, Cirmtuzumab (UC-961), And The Bruton Tyrosine Kinase Inhibitor, Ibrutinib, In Patients With B-Cell Lymphoid Malignancies

DISEASE GROUP:

Lymphoma

current phase:

Phase I/II

STUDY STATUS:

Accepting Patients

Location:

Hackensack, NJ

For More information:

Call 201-518-3587